Trip dialogue predicted sobriety — and ketamine works via adenosine, not just NMDA receptors

Key Findings

🔋 Ketamine's Antidepressant Effects May Work Through Energy Metabolism, Not Just Brain Receptors

• New research suggests ketamine, ECT, and acute intermittent hypoxia all trigger rapid antidepressant effects through adenosine signaling—the same molecule involved in cellular energy and sleep regulation

• The mechanism primarily involves modulation of mitochondrial metabolism rather than NMDA receptor antagonism, which has been the leading theory for ketamine's effects

• This metabolic pathway could explain why chronic caffeine use (which blocks adenosine) might interfere with treatment response in depression

💊 Racemic Ketamine Performs Nearly as Well as Expensive Esketamine

• 76 patients with treatment-resistant depression received either FDA-approved intranasal esketamine or off-label racemic ketamine over 4 weeks

• Both groups showed similar symptom improvement (-9.3 vs -10.0 points on depression scales), meeting non-inferiority criteria

• Esketamine had higher remission rates (38.7% vs 15.6%), but racemic ketamine could offer a more accessible and affordable alternative where esketamine access is limited

🧬 DNA Methylation Patterns Predict Ketamine Response in PTSD

• Machine learning analysis of pre-treatment blood samples from PTSD patients identified 1,208 methylation sites that predicted ketamine treatment response with 92.9% accuracy

• The predictive DNA methylation sites were enriched near genes involved in glutamatergic signaling and immune regulation, as well as established PTSD risk loci

• This came from the largest randomized ketamine-PTSD study, which found no overall benefit of ketamine over placebo, highlighting the need to identify responsive subgroups

⚡ More Preparation Therapy Sessions Boost Psychedelic Treatment Outcomes

• Meta-analysis of 12 controlled trials with 733 participants found that more hours of preparation therapy before psychedelic dosing was significantly associated with greater symptom reduction

• Psychedelic-assisted therapy showed large overall effects (Hedges g = -0.84) compared to control conditions across all studies

• Hours of post-dosing integration therapy and total session count showed no significant association with outcomes, suggesting preparation may be the critical therapeutic component

📈 ECT Works Faster Than Ketamine for Severe Depression

• Meta-analysis of 7 studies with 731 participants found ECT led to faster improvement than ketamine, with approximately 0.02 standardized mean difference per day

• By the end of 4 weeks, ECT showed a projected moderate efficacy advantage (SMD = 0.59) over ketamine for major depressive disorder

• Patients receiving ketamine had significantly lower depression scores at baseline compared to ECT patients, suggesting different severity populations

🎯 Mindset Matters More Than Molecule Type for Mystical Experiences

• 397 adults reported on their most intense experiences with psilocybin, MDMA, or cannabis—psilocybin and MDMA produced greater mystical experiences than cannabis, but effect sizes were small (β = 0.14-0.34)

• When psychological factors were included, mindset variables like surrendering to the experience and spiritual motivations accounted for up to 58% of variance in mystical experiences

• Substance type alone accounted for only 10% of variance, with 83% reporting recreational use and 75% using other substances concurrently